07:43 AM EDT, 05/06/2024 (MT Newswires) -- Redhill Biopharma ( RDHL ) said Monday it was awarded a new patent in China for investigational drug opaganib as a therapy to inhibit single-stranded RNA virus replication, notably Ebola virus disease.

The patent, issued by the Chinese National Intellectual Property Administration, is valid through 2035, according to Redhill.

The company said opaganib is an investigational host-directed and potentially broad-acting drug that targets multiple diseases, including gastrointestinal acute radiation syndrome, COVID-19 as well as other viruses, and bile duct cancer.

RedHill Chief Business Officer Guy Goldberg said the new patent is the "first China patent in the Ebola patent family."

Redhill shares were more than 5% higher in recent premarket activity Monday.

Price: 0.4731, Change: +0.02, Percent Change: +5.16